{
  "id": 10994718,
  "title": "Experimental obesity drug targets appetite through amylin, offering potential alternative to GLP-1 therapies",
  "url": "https://urgent.news/2026/09/30/experimental-obesity-drug-targets-appetite-through-amylin-offering",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-30T17:00:11.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-09-experimental-obesity-drug-appetite-amylin.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept. 28–Oct. 2), and published in The Lancet Diabetes & Endocrinology shows that weekly injections of the new amylin-based obesity drug petrelintide can enable those treated to lose more than 10% of their body weight—generally less weight loss than with existing…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}